4‑bromo‑1‑butyl‑1H‑pyridin‑2‑one | 1127499-22-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4‑bromo‑1‑butyl‑1H‑pyridin‑2‑one
• 英文别名: 4-bromo-1-butylpyridin-2(1H)-one；4-bromo-1-butylpyridin-2-one
• CAS: 1127499-22-2
• 化学式: C₉H₁₂BrNO
• 分子量: 230.104
• InChiKey: YGDYYFREKABGJV-UHFFFAOYSA-N

物化性质

• 沸点：
  301.1±35.0 °C(Predicted)
• 密度：
  1.406±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4‑bromo‑1‑butyl‑1H‑pyridin‑2‑one 在 N-氯代丁二酰亚胺 、 palladium diacetate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 sodium t-butanolate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 16.17h， 生成 1-丁基-3-氯-4-(4-苯基哌啶-1-基)吡啶-2(1H)-酮
  参考文献：
  名称：

  Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor

  摘要：

  We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders.

  DOI：

  10.1021/jm500496m
• 作为产物：
  描述：

  4-benzyloxy-1-butyl-1H-pyridin-2-one 在 palladium on activated charcoal 、 氢气 、 三溴氧磷 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 4‑bromo‑1‑butyl‑1H‑pyridin‑2‑one
  参考文献：
  名称：

  Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor

  摘要：

  We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this article, we describe a different exploration from 5 that led to the discovery of a novel subseries of phenylpiperidine-substituted pyridones. The optimization strategy involved the introduction of different spacers between the pyridone core and the phenyl ring of 5. The fine tuning of metabolism and hERG followed by differentiation of advanced leads that were identified on the basis of PK profiles and in vivo potency converged on lead compound 36 (JNJ-40411813). Full in vitro and in vivo profiles indicate that 36 displayed an optimal interplay between potency, selectivity, favorable ADMET/PK and cardiovascular safety profile, and central EEG activity. Compound 36 has been investigated in the clinic for schizophrenia and anxious depression disorders.

  DOI：

  10.1021/jm500496m

文献信息

• Iridium-Catalysed C–H Borylation of 2-Pyridones; Bisfunctionalisation of CC4
  作者：Hugo Campello、Timothy Gallagher、Aurélien Honraedt、Worawat Niwetmarin、Cecilia Gotti

  DOI：10.1055/s-0036-1591594

  日期：2018.9

  Abstract The high regioselectivity associated with the iridium-catalysed borylation of pyridones has been exploited to provide a very direct and efficient entry to C(10) doubly substituted CC4 variants of cytisine. Two approaches have been evaluated based on (i) C–H activation of cytisine (or an N-substituted derivative) followed by N-alkylation (to enable dimer formation) and (ii) direct C–H activation and

  摘要 与铱催化的吡啶酮的硼化作用相关的高区域选择性已被利用来提供一个非常直接和有效的进入胱氨酸的C（10）双取代的CC4变体的途径。基于（i）半胱氨酸（或N-取代的衍生物）的C–H活化，随后的N-烷基化（以使二聚体形成）和（ii）CC4的直接C–H活化和硼化，已评估了两种方法。两种方法都提供了对C（10）-官能化CC4衍生物的访问，但是CC4的直接硼酸酯化允许更广泛的官能团互变。 与铱催化的吡啶酮的硼化作用相关的高区域选择性已被利用来提供一个非常直接和有效的进入胱氨酸的C（10）双取代的CC4变体的途径。基于（i）半胱氨酸（或N-取代的衍生物）的C–H活化，随后的N-烷基化（以使二聚体形成）和（ii）CC4的直接C–H活化和硼化，已评估了两种方法。两种方法都提供了对C（10）-官能化CC4衍生物的访问，但是CC4的直接硼酸酯化允许更广泛的官能团互变。
• [EN] 1,3-DISUBSTITUTED-4-PHENYL-1 H-PYRIDIN-2-ONES<br/>[FR] 4-PHÉNYLE-1H-PYRIDINE-2-ONES 1,3-DISUBSTITUÉES
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2009033703A1

  公开（公告）日：2009-03-19

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖化合物，特别是根据式（I）的新型吡啶酮衍生物，其中所有基团如申请和权利要求中所定义。根据本发明的化合物是代谢型受体-亚型2（'mGluR2'）的阳性变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及涉及代谢型受体mGluR2亚型的疾病。具体来说，这些疾病是中枢神经系统疾病，包括焦虑、精神分裂症、偏头痛、抑郁症和癫痫等。该发明还涉及制备这种化合物和组合物的药物组合物和过程，以及利用这种化合物预防和治疗涉及mGluR2的疾病。
• [EN] 1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES<br/>[FR] 4-PHÉNYL-3,4,5,6-TÉTRAHYDRO-2H,1'H-[1, 4'] BIPYRIDINYL-2'-ONES 1', 3'-DISUSBSTITUÉES
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2009033704A1

  公开（公告）日：2009-03-19

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ('mGluR2') which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新型化合物，特别是根据式（I）中定义的新型吡啶酮衍生物，其中所有基团均如申请和权利要求中所定义。根据本发明的化合物是代谢型受体亚型2（'mGluR2'）的阳性变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经系统和精神疾病，以及mGluR2代谢型受体亚型涉及的疾病。具体来说，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病的选择性疾病。本发明还涉及制备这种化合物和组合物的药物组合物和方法，以及利用这种化合物预防和治疗mGluR2涉及的疾病。
• 3-AZABICYCLO[3.1.0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Cid-Nunez Jose Maria

  公开号：US20110306642A1

  公开（公告）日：2011-12-15

  The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖化合物，特别是根据式（I）中定义的新型吡啶酮衍生物，其中所有基团均如申请和权利要求中所定义。根据本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍，以及涉及代谢型受体亚型mGluR2的疾病。特别是，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统障碍的疾病。该发明还涉及制备这种化合物和组合物的药物组合物和工艺，以及利用这种化合物预防和治疗涉及mGluR2的这种疾病。
• Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors
  作者：Jitendra A. Sattigeri、Malvika Garg、Pragya Bhateja、Ajay Soni、Abdul Rehman Abdul Rauf、Mahendrakumar Gupta、Mahesh S. Deshmukh、Tarun Jain、Nidhi Alekar、Tarani Kanta Barman、Paras Jha、Tridib Chaira、Ramesh B. Bambal、Dilip J. Upadhyay、Takahide Nishi

  DOI：10.1016/j.bmcl.2018.06.017

  日期：2018.9

  alternative to treat urinary tract infections caused by UPEC. Herein, we report that compounds having the S-glycosidic bond (thiomannosides) had improved metabolic stability and plasma exposures when dosed orally. Especially compound 5h showed the potential to inhibit biofilm formation and also to disrupt the preformed biofilm. And compound 5h showed prophylactic effect in UTI model in mice.

  FimH是一种I型纤维凝集素，位于革兰氏阴性尿路致病性大肠杆菌（UPEC）的1型菌毛末端，指导其粘附和感染尿道上皮细胞的能力。因此，用小分子抑制剂阻断FimH被认为是治疗由UPEC引起的尿路感染的有前途的新治疗选择。本文中，我们报道口服给药时具有S-糖苷键的化合物（硫甘露糖苷）具有改善的代谢稳定性和血浆暴露。特别是化合物5h显示出抑制生物膜形成并破坏预形成的生物膜的潜力。化合物5h在小鼠UTI模型中具有预防作用。